Bone turnover markers (BTM) provide useful data to titrate the optimal dosing regimes for patients within 3-6 months as compared to 1-2 years using bone mineral density (BMD). Serum obtained under standardised conditions (fasting, early morning) should be tested using a precise automated immunoassay for a panel of bone markers that includes a resorption marker -C-terminal cross-linked telopeptide of bone collagen (CTX) -and formation markers -Procollagen Type 1 N-terminal Propeptide (P1NP) and Osteocalcin (OC).
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BAcKGrOUND
Bone comprises a protein matrix formed by osteoblasts which is subsequently mineralised by calcium and phosphate. Bone surfaces are covered by osteoblasts, osteocytes and osteoclasts 1 . Old bone is removed by osteoclasts (bone resorption) and new bone is rebuilt by osteoblasts (bone formation). This continuous process of remodelling maintains normal skeletal and bone health. Normally, there is a balance between resorption and formation. However, with age and menopause the imbalance favours resorption resulting in decreased bone mineral density (BMD) and increased risk of fractures associated with minimal trauma or falls.
Tests commonly Included
Serum Procollagen Type 1 N-terminal Propeptide (P1NP), and C-terminal cross-linked telopeptide of bone collagen (CTX), and Osteocalcin (OC) Bone turnover markers (BTMs) are generally classified as markers of resorption and formation 2 . Resorption markers are either osteoclastic enzymes or products of collagen degradation e.g. peptidebound carboxy-telopeptide crosslinks of type I collagen (CTX), released into the circulation. Formation markers are either osteoblastic enzymes or breakdown products e.g. procollagen-type1amino-propeptide (P1NP), a more specific marker for bone collagen synthesis than the carboxypropetide. Enzyme markers are less stable and less precise analytically and should be discontinued. Osteocalcin (OC) is an abundant noncollagenous matrix protein in bone produced by osteoblasts. Some OC fragments are detected in urine and may reflect bone matrix degradation. Thus OC could also represent a degree of bone resorption. As such, OC would provide additional information to the use of P1NP and CTX. follow-up session 3 . Urine is not recommended. A baseline BTM prior to the commencement of therapy and 3-6 months after initiating treatment is ideal 4 .
INDIcATIONs
BTM measurements complement BMD to identify candidates for intervention 5 . Bone quality is compromised when there is a high bone turnover and such patients may benefit from anti-resorptive therapies. Compliance with therapy is often poor and the monitoring of treatment relies on surrogate markers like BTM. Unusual subtrochanteric fractures after treatment with longterm bisphosphonates as well as osteonecrosis of the jaw have been reported and maybe minimised by BTM monitoring 6 . BTM is helpful as an index of treatment efficacy, compliance and prognosis for future fractures. Anti-resorptive treatment (biphosphonates, raloxifene, oestrogens, calcitonin) is associated with a reduction in resorption markers, whereas treatment with the anabolic PTH peptide (teriparatide) is accompanied by a rapid increase in bone formation markers followed by an increase in resorption markers 7, 8 .
Strontium ranelate does not influence bone turnover markers significantly.
Methodology Previously, BTMs were tested using demanding and labour-intensive methods [e.g. High Performance Liquid Chromatography (HPLC), Radioimmunoassay (RIA), Enzyme immunoassay (EIA) on urine samples. The greater biological variability of urinary BTMs and the requirement for creatinine correction renders urinary measurements less reliable. Preanalytical factors, such as circadian rhythm and diet, have also impacted the usage of BTM. However, the availability of rapid (<30 min), automated immunochemiluminometric assays 9,10 (Elecsys, Roche) on serum with high precision and inter-day variability (4-6%) has enabled same session results for the bone clinic.
Limitations
While BTMs may reflect bone turnover (formation and/or resorption) they do not indicate the cause and should not replace imaging for diagnosis 7 . When interpreting BTM results, doctors must be cognizant of the patient's condition 2 . BTM values may increase by 20-50% and remain elevated for 6-12 months after a bone fracture. Renal impairment will raise OC and other markers metabolised by the kidney especially when creatinine clearance falls below 30mL/min. Drugs may increase (anticonvulsants, GnRH agonists and oral contraceptives) or decrease (thiazides) BTM concentrations. Intra-individual variability arises from calcium intake, circadian rhythm and exercise. Intra-patient variability in serum CTX is halved when compared with urinary measurements. Moreover, fasting significantly reduced the average circadian variation in serum CTX from 36 to 8.7%.
The lack of wider utility of BTMs may be attributed to previous analytical shortcomings and the under appreciation of pre-analytical issues.
NEW DEVELOPMENTs
A monoclonal antibody against receptor activator of nuclear-factor kappa-B ligand (RANKL), denosumab, is now available for treatment of osteoporosis 11, 12 . Bone resorption is influenced by osteoblasts through the interaction between receptor activator of nuclear-factor kappa-B (RANK) and RANKL. Osteoblasts produce RANKL, a cytokine of the tumour necrosis factor (TNF) family. RANK resides on the surface of osteoclasts and pre-osteoclasts. RANK-RANKL binding stimulates the formation, activation and maturation of osteoclasts. Osteoblasts produce another TNF cytokine, osteoprotegerin (OPG), which can bind RANKL thus inhibit RANK-RANKL interaction. The relative balance between RANKL and OPG determines osteoclast activity. Activated osteoclasts produce enzymes that degrade bone matrix. The exact interaction between osteoclasts and osteoblasts remains unclear but continues to evolve with new knowledge [13] [14] [15] [16] . New treatment approaches spring from new understandings of bone biology 17, 18 .
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